NAASO GUIDELINES ON ANTI-OBESITY DRUGS EXPECTED BY NOVEMBER
NAASO GUIDELINES ON ANTI-OBESITY DRUGS EXPECTED BY NOVEMBER, the North American Association for the Study of Obesity reports. The "Guidelines for the Development, Approval and Use of Drugs to Treat Obesity" are under review by the society and should be finalized in four to six weeks, NAASO said. They will be published in the society's Journal of Obesity Research. The guidelines were co-authored by NAASO President Xavier Pi-Sunyer, MD, St. Luke's Hospital, and Judy Stem, University of California-Davis.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth